Current race in the development of DAAs (direct-acting antivirals) against HCV
The direct-acting antivirals (DAAs) currently in development for treatment of hepatitis C fall into four categories: (i) NS3/4A protease inhibitors: ABT-450/r, faldaprevir, asunaprevir, GS-9256, vedroprevir (GS-9451), danoprevir, MK-5172, vaniprevir, sovaprevir, ACH-2684, narlaprevir and simeprevir,...
Gespeichert in:
| Veröffentlicht in: | Biochemical pharmacology 2014-06, Vol.89 (4), p.441-452 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 452 |
|---|---|
| container_issue | 4 |
| container_start_page | 441 |
| container_title | Biochemical pharmacology |
| container_volume | 89 |
| creator | De Clercq, Erik |
| description | The direct-acting antivirals (DAAs) currently in development for treatment of hepatitis C fall into four categories: (i) NS3/4A protease inhibitors: ABT-450/r, faldaprevir, asunaprevir, GS-9256, vedroprevir (GS-9451), danoprevir, MK-5172, vaniprevir, sovaprevir, ACH-2684, narlaprevir and simeprevir, in addition to those that are already developed [telaprevir (Incivek®) and boceprevir (Victrelis®)], (ii) NS5A protein inhibitors: ABT-267, daclatasvir, ledipasvir, ACH-2928, ACH-3102, PPI-668, AZD-7295, MK-8742, and GSK 2336805; (iii) NS5B (nucleoside-type) polymerase inhibitors: sofosbuvir (now approved by the FDA since 6 December 2013), GS-0938, mericitabine, VX-135, ALS 2158 and TMC 649128; (iv) NS5B (non-nucleoside-type) polymerase inhibitors: VX-222, ABT-072, ABT-333, deleobuvir, tegobuvir, setrobuvir, VCH-916, VCH-759, BMS-791325 and TMC-647055. Future drug combinations will likely exist of two or more DAAs belonging to any of the 4 categories, with the aim to achieve (i) pan-genotypic hepatitis C virus (HCV) activity, (ii) little or no risk for resistance; (iii) short duration (i.e. 12 weeks) of treatment, and (iv) a sustained viral response (SVR) and definite cure of the disease. |
| doi_str_mv | 10.1016/j.bcp.2014.04.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1544018816</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006295214002299</els_id><sourcerecordid>1544018816</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-5667d6156add65930258ee6ddb3c349b28386c54ff91c65b67e7f0efec85fd243</originalsourceid><addsrcrecordid>eNqNkE1LwzAYx4Mobk4_gBfJcR5ak7ZJUzyN-jJh6EW9hjR5OjO2dibtwG9vyqZHER54Xvg9_8MPoUtKYkoov1nFld7GCaFZTEIRdoTGVORplBRcHKMxIYSHmSUjdOb9algFp6dolGR5yjhNx-i57J2DpsNOacC2wd0HYAM7WLfbzXBva3w3m3k8NdaB7iKlO9sssWo6u7NOrf01VktlG9_hefl-jk7qcIOLQ5-gt4f713IeLV4en8rZItKp4F3EOM8Np4wrYzgrUpIwAcCNqVKdZkWViIBpltV1QTVnFc8hrwnUoAWrTZKlEzTd525d-9mD7-TGeg3rtWqg7b2kLMsIFYLyf6CJEILllAWU7lHtWu8d1HLr7Ea5L0mJHIzLlQzG5WBcklBk-Lk6xPfVBszvx4_iANzuAQg-dhac9NpCo2EvVJrW_hH_DQsTjyw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1528885715</pqid></control><display><type>article</type><title>Current race in the development of DAAs (direct-acting antivirals) against HCV</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>De Clercq, Erik</creator><creatorcontrib>De Clercq, Erik</creatorcontrib><description>The direct-acting antivirals (DAAs) currently in development for treatment of hepatitis C fall into four categories: (i) NS3/4A protease inhibitors: ABT-450/r, faldaprevir, asunaprevir, GS-9256, vedroprevir (GS-9451), danoprevir, MK-5172, vaniprevir, sovaprevir, ACH-2684, narlaprevir and simeprevir, in addition to those that are already developed [telaprevir (Incivek®) and boceprevir (Victrelis®)], (ii) NS5A protein inhibitors: ABT-267, daclatasvir, ledipasvir, ACH-2928, ACH-3102, PPI-668, AZD-7295, MK-8742, and GSK 2336805; (iii) NS5B (nucleoside-type) polymerase inhibitors: sofosbuvir (now approved by the FDA since 6 December 2013), GS-0938, mericitabine, VX-135, ALS 2158 and TMC 649128; (iv) NS5B (non-nucleoside-type) polymerase inhibitors: VX-222, ABT-072, ABT-333, deleobuvir, tegobuvir, setrobuvir, VCH-916, VCH-759, BMS-791325 and TMC-647055. Future drug combinations will likely exist of two or more DAAs belonging to any of the 4 categories, with the aim to achieve (i) pan-genotypic hepatitis C virus (HCV) activity, (ii) little or no risk for resistance; (iii) short duration (i.e. 12 weeks) of treatment, and (iv) a sustained viral response (SVR) and definite cure of the disease.</description><identifier>ISSN: 0006-2952</identifier><identifier>EISSN: 1873-2968</identifier><identifier>DOI: 10.1016/j.bcp.2014.04.005</identifier><identifier>PMID: 24735613</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Animals ; Antiviral Agents - adverse effects ; Antiviral Agents - chemistry ; Antiviral Agents - pharmacology ; Antiviral Agents - therapeutic use ; Direct-acting antivirals ; Drug Discovery ; Drug Resistance, Viral ; Drug Therapy, Combination ; Enzyme Inhibitors - adverse effects ; Enzyme Inhibitors - chemistry ; Enzyme Inhibitors - pharmacology ; Enzyme Inhibitors - therapeutic use ; Hepacivirus - drug effects ; Hepacivirus - enzymology ; Hepatitis C - drug therapy ; Hepatitis C - virology ; Hepatitis C virus ; Hepatitis C virus (HCV) ; Humans ; Molecular Targeted Therapy ; NS3/4A protease inhibitors ; NS5A protein inhibitors ; NS5B (non-nucleoside-type) polymerase inhibitors ; NS5B (nucleoside-type) polymerase inhibitors ; Viral Nonstructural Proteins - antagonists & inhibitors</subject><ispartof>Biochemical pharmacology, 2014-06, Vol.89 (4), p.441-452</ispartof><rights>2014 Elsevier Inc.</rights><rights>Copyright © 2014 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-5667d6156add65930258ee6ddb3c349b28386c54ff91c65b67e7f0efec85fd243</citedby><cites>FETCH-LOGICAL-c386t-5667d6156add65930258ee6ddb3c349b28386c54ff91c65b67e7f0efec85fd243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bcp.2014.04.005$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24735613$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>De Clercq, Erik</creatorcontrib><title>Current race in the development of DAAs (direct-acting antivirals) against HCV</title><title>Biochemical pharmacology</title><addtitle>Biochem Pharmacol</addtitle><description>The direct-acting antivirals (DAAs) currently in development for treatment of hepatitis C fall into four categories: (i) NS3/4A protease inhibitors: ABT-450/r, faldaprevir, asunaprevir, GS-9256, vedroprevir (GS-9451), danoprevir, MK-5172, vaniprevir, sovaprevir, ACH-2684, narlaprevir and simeprevir, in addition to those that are already developed [telaprevir (Incivek®) and boceprevir (Victrelis®)], (ii) NS5A protein inhibitors: ABT-267, daclatasvir, ledipasvir, ACH-2928, ACH-3102, PPI-668, AZD-7295, MK-8742, and GSK 2336805; (iii) NS5B (nucleoside-type) polymerase inhibitors: sofosbuvir (now approved by the FDA since 6 December 2013), GS-0938, mericitabine, VX-135, ALS 2158 and TMC 649128; (iv) NS5B (non-nucleoside-type) polymerase inhibitors: VX-222, ABT-072, ABT-333, deleobuvir, tegobuvir, setrobuvir, VCH-916, VCH-759, BMS-791325 and TMC-647055. Future drug combinations will likely exist of two or more DAAs belonging to any of the 4 categories, with the aim to achieve (i) pan-genotypic hepatitis C virus (HCV) activity, (ii) little or no risk for resistance; (iii) short duration (i.e. 12 weeks) of treatment, and (iv) a sustained viral response (SVR) and definite cure of the disease.</description><subject>Animals</subject><subject>Antiviral Agents - adverse effects</subject><subject>Antiviral Agents - chemistry</subject><subject>Antiviral Agents - pharmacology</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Direct-acting antivirals</subject><subject>Drug Discovery</subject><subject>Drug Resistance, Viral</subject><subject>Drug Therapy, Combination</subject><subject>Enzyme Inhibitors - adverse effects</subject><subject>Enzyme Inhibitors - chemistry</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Hepacivirus - drug effects</subject><subject>Hepacivirus - enzymology</subject><subject>Hepatitis C - drug therapy</subject><subject>Hepatitis C - virology</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C virus (HCV)</subject><subject>Humans</subject><subject>Molecular Targeted Therapy</subject><subject>NS3/4A protease inhibitors</subject><subject>NS5A protein inhibitors</subject><subject>NS5B (non-nucleoside-type) polymerase inhibitors</subject><subject>NS5B (nucleoside-type) polymerase inhibitors</subject><subject>Viral Nonstructural Proteins - antagonists & inhibitors</subject><issn>0006-2952</issn><issn>1873-2968</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkE1LwzAYx4Mobk4_gBfJcR5ak7ZJUzyN-jJh6EW9hjR5OjO2dibtwG9vyqZHER54Xvg9_8MPoUtKYkoov1nFld7GCaFZTEIRdoTGVORplBRcHKMxIYSHmSUjdOb9algFp6dolGR5yjhNx-i57J2DpsNOacC2wd0HYAM7WLfbzXBva3w3m3k8NdaB7iKlO9sssWo6u7NOrf01VktlG9_hefl-jk7qcIOLQ5-gt4f713IeLV4en8rZItKp4F3EOM8Np4wrYzgrUpIwAcCNqVKdZkWViIBpltV1QTVnFc8hrwnUoAWrTZKlEzTd525d-9mD7-TGeg3rtWqg7b2kLMsIFYLyf6CJEILllAWU7lHtWu8d1HLr7Ea5L0mJHIzLlQzG5WBcklBk-Lk6xPfVBszvx4_iANzuAQg-dhac9NpCo2EvVJrW_hH_DQsTjyw</recordid><startdate>20140615</startdate><enddate>20140615</enddate><creator>De Clercq, Erik</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>20140615</creationdate><title>Current race in the development of DAAs (direct-acting antivirals) against HCV</title><author>De Clercq, Erik</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-5667d6156add65930258ee6ddb3c349b28386c54ff91c65b67e7f0efec85fd243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>Antiviral Agents - adverse effects</topic><topic>Antiviral Agents - chemistry</topic><topic>Antiviral Agents - pharmacology</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Direct-acting antivirals</topic><topic>Drug Discovery</topic><topic>Drug Resistance, Viral</topic><topic>Drug Therapy, Combination</topic><topic>Enzyme Inhibitors - adverse effects</topic><topic>Enzyme Inhibitors - chemistry</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Hepacivirus - drug effects</topic><topic>Hepacivirus - enzymology</topic><topic>Hepatitis C - drug therapy</topic><topic>Hepatitis C - virology</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C virus (HCV)</topic><topic>Humans</topic><topic>Molecular Targeted Therapy</topic><topic>NS3/4A protease inhibitors</topic><topic>NS5A protein inhibitors</topic><topic>NS5B (non-nucleoside-type) polymerase inhibitors</topic><topic>NS5B (nucleoside-type) polymerase inhibitors</topic><topic>Viral Nonstructural Proteins - antagonists & inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>De Clercq, Erik</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Biochemical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>De Clercq, Erik</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current race in the development of DAAs (direct-acting antivirals) against HCV</atitle><jtitle>Biochemical pharmacology</jtitle><addtitle>Biochem Pharmacol</addtitle><date>2014-06-15</date><risdate>2014</risdate><volume>89</volume><issue>4</issue><spage>441</spage><epage>452</epage><pages>441-452</pages><issn>0006-2952</issn><eissn>1873-2968</eissn><abstract>The direct-acting antivirals (DAAs) currently in development for treatment of hepatitis C fall into four categories: (i) NS3/4A protease inhibitors: ABT-450/r, faldaprevir, asunaprevir, GS-9256, vedroprevir (GS-9451), danoprevir, MK-5172, vaniprevir, sovaprevir, ACH-2684, narlaprevir and simeprevir, in addition to those that are already developed [telaprevir (Incivek®) and boceprevir (Victrelis®)], (ii) NS5A protein inhibitors: ABT-267, daclatasvir, ledipasvir, ACH-2928, ACH-3102, PPI-668, AZD-7295, MK-8742, and GSK 2336805; (iii) NS5B (nucleoside-type) polymerase inhibitors: sofosbuvir (now approved by the FDA since 6 December 2013), GS-0938, mericitabine, VX-135, ALS 2158 and TMC 649128; (iv) NS5B (non-nucleoside-type) polymerase inhibitors: VX-222, ABT-072, ABT-333, deleobuvir, tegobuvir, setrobuvir, VCH-916, VCH-759, BMS-791325 and TMC-647055. Future drug combinations will likely exist of two or more DAAs belonging to any of the 4 categories, with the aim to achieve (i) pan-genotypic hepatitis C virus (HCV) activity, (ii) little or no risk for resistance; (iii) short duration (i.e. 12 weeks) of treatment, and (iv) a sustained viral response (SVR) and definite cure of the disease.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>24735613</pmid><doi>10.1016/j.bcp.2014.04.005</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-2952 |
| ispartof | Biochemical pharmacology, 2014-06, Vol.89 (4), p.441-452 |
| issn | 0006-2952 1873-2968 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1544018816 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Animals Antiviral Agents - adverse effects Antiviral Agents - chemistry Antiviral Agents - pharmacology Antiviral Agents - therapeutic use Direct-acting antivirals Drug Discovery Drug Resistance, Viral Drug Therapy, Combination Enzyme Inhibitors - adverse effects Enzyme Inhibitors - chemistry Enzyme Inhibitors - pharmacology Enzyme Inhibitors - therapeutic use Hepacivirus - drug effects Hepacivirus - enzymology Hepatitis C - drug therapy Hepatitis C - virology Hepatitis C virus Hepatitis C virus (HCV) Humans Molecular Targeted Therapy NS3/4A protease inhibitors NS5A protein inhibitors NS5B (non-nucleoside-type) polymerase inhibitors NS5B (nucleoside-type) polymerase inhibitors Viral Nonstructural Proteins - antagonists & inhibitors |
| title | Current race in the development of DAAs (direct-acting antivirals) against HCV |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T07%3A54%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20race%20in%20the%20development%20of%20DAAs%20(direct-acting%20antivirals)%20against%20HCV&rft.jtitle=Biochemical%20pharmacology&rft.au=De%20Clercq,%20Erik&rft.date=2014-06-15&rft.volume=89&rft.issue=4&rft.spage=441&rft.epage=452&rft.pages=441-452&rft.issn=0006-2952&rft.eissn=1873-2968&rft_id=info:doi/10.1016/j.bcp.2014.04.005&rft_dat=%3Cproquest_cross%3E1544018816%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1528885715&rft_id=info:pmid/24735613&rft_els_id=S0006295214002299&rfr_iscdi=true |